TSA Suppresses miR-106b-93-25 Cluster Expression through Downregulation of MYC and Inhibits Proliferation and Induces Apoptosis in Human EMC

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhao, Zhi Ning ^a,c   Bai, Jiu Xu ^a,d   Zhou, Qiang ^a   Yan, Bo ^a   Qin, Wei Wei ^b   Jia, Lin Tao ^a   Meng, Yan Ling ^a   Jin, Bo Quan ^a   Yao, Li Bo ^a   Wang, Tao ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c 451 Hospital of Chinese People's Liberation Army   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; MICRORNA; MICRORNA 106B 93 25; MINICHROMOSOME MAINTENANCE PROTEIN 7; MYC PROTEIN; PROTEIN P21; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIM GENE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCM7 GENE; P21 GENE; PLASMID; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR GENE; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOWN-REGULATION; E-BOX ELEMENTS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MICRORNAS; MULTIGENE FAMILY; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER;

EID: 84866552673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045133     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Di Cristofano A, Ellenson LH, (2007) Endometrial carcinoma. Annu Rev Pathol 2: 57-85.
3. Smith LT, Otterson GA, Plass C, (2007) Unraveling the epigenetic code of cancer for therapy. Trends Genet 23: 449-456.
4. Hake SB, Xiao A, Allis CD, (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 90: 761-769.
5. Szyf M, (2005) DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc) 70: 533-549.
6. Xiong Y, Dowdy SC, Eberhardt NL, Podratz KC, Jiang SW, (2006) hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol 103: 321-328.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
8. Johnstone RW, (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
9. Glozak MA, Seto E, (2007) Histone deacetylases and cancer. Oncogene 26: 5420-5432.
10. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
11. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
12. Shin S, Lee EM, Cha HJ, Bae S, Jung JH, et al. (2009) MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 35: 1343-1352.
13. Cole MD, Nikiforov MA, (2006) Transcriptional activation by the Myc oncoprotein. Curr Top Microbiol Immunol 302: 33-50.
14. Wu H, Chen Y, Liang J, Shi B, Wu G, et al. (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438: 981-987.
15. Kim YK, Kim VN, (2007) Processing of intronic microRNAs. EMBO J 26: 775-783.
16. Blow JJ, Hodgson B, (2002) Replication licensing-defining the proliferative state? Trends Cell Biol 12: 72-78.
17. Ren B, Yu G, Tseng GC, Cieply K, Gavel T, et al. (2006) MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25: 1090-1098.
18. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, et al. (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28: 2167-2174.
19. Li H, Wu X, (2004) Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 324: 860-867.
20. Noh EJ, Lee JS, (2003) Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun 310: 267-273.
21. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, et al. (2003) Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 38: 59-69.
22. Roy S, Packman K, Jeffrey R, Tenniswood M, (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491.
23. Ayer DE, Kretzner L, Eisenman RN, (1993) Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222.
24. Boyd KE, Farnham PJ, (1997) Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol 17: 2529-2537.
25. Jenuwein T, Allis CD, (2001) Translating the histone code. Science 293: 1074-1080.
26. Feinberg AP, Ohlsson R, Henikoff S, (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
27. Santini V, Gozzini A, Ferrari G, (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.
28. Lin HY, Chen CS, Lin SP, Weng JR, (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397-413.
29. Noh EJ, Lim DS, Jeong G, Lee JS, (2009) An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378: 326-331.
30. Wu Y, Guo SW, (2008) Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 137: 198-203.
31. Wu Y, Guo SW, (2006) Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62: 193-205.
32. Wu Y, Guo SW, (2007) Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 135: 88-93.
33. Wu Y, Starzinski-Powitz A, Guo SW, (2010) Constitutive and tumor necrosis factor-alpha-stimulated activation of nuclear factor-kappaB in immortalized endometriotic cells and their suppression by trichostatin A. Gynecol Obstet Invest 70: 23-33.
34. Wu Y, Starzinski-Powitz A, Guo SW, (2007) Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 14: 374-382.
35. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, et al. (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149.
36. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, et al. (2006) Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5: 2767-2776.
37. Kim YK, Yu J, Han TS, Park SY, Namkoong B, et al. (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 37: 1672-1681.
38. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
39. Kan T, Meltzer SJ, (2009) MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 9: 727-732.
40. Li Y, Tan W, Neo TW, Aung MO, Wasser S, et al. (2009) Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 100: 1234-1242.
41. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 105: 12885-12890.
42. Maiorano D, Lutzmann M, Mechali M, (2006) MCM proteins and DNA replication. Curr Opin Cell Biol 18: 130-136.
43. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, et al. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272-286.
44. Suzuki S, Adachi A, Hiraiwa A, Ohashi M, Ishibashi M, et al. (1998) Cloning and characterization of human MCM7 promoter. Gene 216: 85-91.
45. O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, et al. (2000) Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet 24: 113-119.
46. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, et al. (1995) Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14: 5646-5659.
47. Xiao H, Hasegawa T, Isobe K, (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371-1376.